{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:59:32Z","timestamp":1771275572782,"version":"3.50.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Many studies have explored the link between the gut microbiota and schizophrenia. To date, there have been no bibliometric analyses to summarize the association between the gut microbiota and schizophrenia. We aimed to conduct a bibliometric study of this association to determine the current status and areas for advancement in this field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Publications related to the gut microbiota and schizophrenia were retrieved from the Web of Science Core Collection (WoSCC). The WoSCC literature analysis wire and VOSviewer 1.6.16 were used to conduct the analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 162 publications were included in our study. The publications generally showed an upward trend from 2014. A total of 873 authors from 355 organizations and 40 countries\/regions contributed to this field. The leading authors were Timothy Dinan, John F Cryan, and Emily Severance. The leading institutions were Johns Hopkins University, the University College Cork, and the University of Toronto. The most productive countries were the United States (US), China, and Canada. In total, 95 journals contributed to this field. Among them, the top three productive journals were Schizophrenia Research, Progress in Neuro Psychopharmacology Biological Psychiatry, and Frontiers in Psychiatry. The important keywords in the clusters were gut microbiome, bipolar disorder, schizophrenia, antipsychotics, weight gain, metabolic syndrome, gut-brain axis, autism, depression, inflammation, and brain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The main research hotspots involving the connection between schizophrenia and the gut microbiota were the characteristics of the microbiota composition in schizophrenia patients, the gut-brain axis, and microbial-based interventions for schizophrenia. The studies about the association between gut microbiota and schizophrenia are limited, and more studies are needed to provide new insights into the gut microbiota in the pathogenesis and treatment of schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1022472","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T05:00:46Z","timestamp":1668488446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["The schizophrenia and gut microbiota: A bibliometric and visual analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Chao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianteng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2215-0366(21)00243-1","article-title":"Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.","volume":"8","author":"Bighelli","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia.","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia.","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics.","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5498\/wjp.v11.i10.696","article-title":"Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: state-of-the-art and future perspectives.","volume":"11","author":"Chang","year":"2021","journal-title":"World J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2020.02.010","article-title":"The role of the gut microbiome in the development of schizophrenia.","volume":"234","author":"Kelly","year":"2021","journal-title":"Schizophr Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2020.02.012","article-title":"The gut-microbiome as a target for the treatment of schizophrenia: a systematic review and meta-analysis of randomised controlled trials of add-on strategies.","volume":"234","author":"Minichino","year":"2021","journal-title":"Schizophr Res."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000492834","article-title":"The role of nutrition and the gut-brain axis in psychiatry: a review of the literature.","author":"Morkl","year":"2018","journal-title":"Neuropsychobiology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fpsyt.2020.00156","article-title":"The gut microbiome and schizophrenia: the current state of the field and clinical applications.","volume":"11","author":"Szeligowski","year":"2020","journal-title":"Front Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbi.2021.09.014","article-title":"Antipsychotic-induced gastrointestinal hypomotility and the alteration in gut microbiota in patients with schizophrenia.","volume":"99","author":"Xu","year":"2022","journal-title":"Brain Behav Immun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/mp.2014.54","article-title":"Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia.","volume":"20","author":"Stan","year":"2015","journal-title":"Mol Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/microorganisms10061121","article-title":"Gut microbiome: a brief review on its role in schizophrenia and first episode of psychosis.","volume":"10","author":"Tsamakis","year":"2022","journal-title":"Microorganisms."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41380-019-0475-4","article-title":"Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice.","volume":"25","author":"Zhu","year":"2020","journal-title":"Mol Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/ajmg.b.32567","article-title":"Microbiome, inflammation, epigenetic alterations, and mental diseases.","volume":"174","author":"Alam","year":"2017","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.biopsych.2018.06.014","article-title":"Programming bugs: microbiota and the developmental origins of brain health and disease.","volume":"85","author":"Codagnone","year":"2019","journal-title":"Biol Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbi.2016.12.010","article-title":"The microbiome, immunity, and schizophrenia and bipolar disorder.","volume":"62","author":"Dickerson","year":"2017","journal-title":"Brain Behav Immunity."},{"key":"B28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/BOR.0b013e32836208de","article-title":"The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness.","volume":"25","author":"Hornig","year":"2013","journal-title":"Curr Opin Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11920-015-0574-0","article-title":"Gastroenterology issues in schizophrenia: why the gut matters.","volume":"17","author":"Severance","year":"2015","journal-title":"Curr Psychiatry Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fnins.2017.00490","article-title":"Cross talk: the microbiota and neurodevelopmental disorders.","volume":"11","author":"Kelly","year":"2017","journal-title":"Front Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpsychires.2018.01.013","article-title":"Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder.","volume":"99","author":"Nguyen","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/mp.2014.93","article-title":"Genomics of schizophrenia: time to consider the gut microbiome?","volume":"19","author":"Dinan","year":"2014","journal-title":"Mol Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41467-020-15457-9","article-title":"Metagenome-wide association of gut microbiome features for schizophrenia.","volume":"11","author":"Zhu","year":"2020","journal-title":"Nat Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.17116\/jnevro202212210157","article-title":"The microbiota-gut-brain axis.","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e115225","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS One."},{"key":"B36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/PSY.0000000000000519","article-title":"Brain-gut-microbiota axis and mental health.","volume":"79","author":"Dinan","year":"2017","journal-title":"Psychosom Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2018.09.014","article-title":"Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects.","volume":"204","author":"Nguyen","year":"2019","journal-title":"Schizophr Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.schres.2017.04.017","article-title":"Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response.","volume":"192","author":"Schwarz","year":"2018","journal-title":"Schizophr Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.schres.2013.05.018","article-title":"Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.","volume":"148","author":"Severance","year":"2013","journal-title":"Schizophr Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2014.06.027","article-title":"Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling.","volume":"176","author":"Severance","year":"2016","journal-title":"Schizophr Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.schres.2018.01.002","article-title":"Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study.","volume":"197","author":"Shen","year":"2018","journal-title":"Schizophr Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"eaau8317","DOI":"10.1126\/sciadv.aau8317","article-title":"The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice.","volume":"5","author":"Zheng","year":"2019","journal-title":"Sci Adv."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1038\/tp.2016.42","article-title":"Regulation of prefrontal cortex myelination by the microbiota.","volume":"6","author":"Hoban","year":"2016","journal-title":"Transl Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2019.12.014","article-title":"Gut microbial changes of patients with psychotic and affective disorders: a systematic review.","volume":"234","author":"Vindegaard","year":"2021","journal-title":"Schizophr Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/nu13041152","article-title":"The gut microbiome in schizophrenia and the potential benefits of prebiotic and probiotic treatment.","volume":"13","author":"Liu","year":"2021","journal-title":"Nutrients."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamapsychiatry.2021.2573","article-title":"Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis.","volume":"78","author":"Nikolova","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.neubiorev.2021.02.044","article-title":"Mining microbes for mental health: determining the role of microbial metabolic pathways in human brain health and disease.","volume":"125","author":"Spichak","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"110097","DOI":"10.1016\/j.pnpbp.2020.110097","article-title":"Gut microbiota: an intermediary between metabolic syndrome and cognitive deficits in schizophrenia.","volume":"106","author":"Zeng","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nature11319","article-title":"Gut microbiota composition correlates with diet and health in the elderly.","volume":"488","author":"Claesson","year":"2012","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3389\/fphar.2018.01040","article-title":"The microbiome: a new target for research and treatment of schizophrenia and its resistant presentations? A systematic literature search and review.","volume":"9","author":"Cuomo","year":"2018","journal-title":"Front Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00213-018-5102-6","article-title":"Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.","volume":"236","author":"Skonieczna-Zydecka","year":"2019","journal-title":"Psychopharmacology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nm.3766","article-title":"Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis.","volume":"21","author":"Crane","year":"2015","journal-title":"Nat Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2017.10.005","article-title":"Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions.","volume":"37","author":"Solas","year":"2017","journal-title":"Curr Opin Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1038\/s41380-019-0425-1","article-title":"Mid-life microbiota crises: middle age is associated with pervasive neuroimmune alterations that are reversed by targeting the gut microbiome.","volume":"25","author":"Boehme","year":"2020","journal-title":"Mol Psychiatry."},{"key":"B55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrgastro.2015.127","article-title":"GUT microbiota: microbiota and neuroimmune signalling-Metchnikoff to microglia.","volume":"12","author":"Cryan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nn.4030","article-title":"Host microbiota constantly control maturation and function of microglia in the CNS.","volume":"18","author":"Erny","year":"2015","journal-title":"Nat Neurosci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnins.2015.00229","article-title":"Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity.","volume":"9","author":"Castanon","year":"2015","journal-title":"Front Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpsychires.2020.02.005","article-title":"Alteration of the gut microbiome in first-episode drug-naive and chronic medicated schizophrenia correlate with regional brain volumes.","volume":"123","author":"Ma","year":"2020","journal-title":"J Psychiatr Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/jcm8101605","article-title":"Analysis of gut microbiota and their metabolic potential in patients with schizophrenia treated with olanzapine: results from a six-week observational prospective cohort study.","volume":"8","author":"Pelka-Wysiecka","year":"2019","journal-title":"J Clin Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbi.2019.06.039","article-title":"Altered gut microbiota and mucosal immunity in patients with schizophrenia.","volume":"85","author":"Xu","year":"2020","journal-title":"Brain Behav Immunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.118.015768","article-title":"Gut reactions: breaking down xenobiotic-microbiome interactions.","volume":"71","author":"Clarke","year":"2019","journal-title":"Pharmacol Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00213-019-5185-8","article-title":"Psychotropics and the microbiome: a chamber of secrets.","volume":"236","author":"Cussotto","year":"2019","journal-title":"Psychopharmacology."},{"key":"B63","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00213-018-5006-5","article-title":"Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function.","volume":"236","author":"Cussotto","year":"2019","journal-title":"Psychopharmacology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/15622975.2018.1540793","article-title":"Schizophrenia and the microbiome: time to focus on the impact of antipsychotic treatment on the gut microbiota.","volume":"19","author":"Dinan","year":"2018","journal-title":"World J Biol Psychiatry."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000494696","article-title":"Investigation of the gut microbiome in patients with schizophrenia and clozapine-induced weight gain: protocol and clinical characteristics of first patient cohorts.","volume":"79","author":"Gorbovskaya","year":"2020","journal-title":"Neuropsychobiology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41398-018-0116-8","article-title":"Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota.","volume":"8","author":"Kao","year":"2018","journal-title":"Transl Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1022472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T05:00:49Z","timestamp":1668488449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1022472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":67,"alternative-id":["10.3389\/fpsyt.2022.1022472"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1022472","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"1022472"}}